|
Interim Results Of High-Dose Calcitriol/Docetaxel
(C/D) Versus Docetaxel (D) In Men With HRPC
(July 2005)
Dr. Beers, Oregon Health Sciences University, has pioneered
the investigation of high-dose calcitriol because of preclinical evidence
that “it enhance[s] the anti-tumor activity of multiple classes of
chemotherapy”. At ASCO he reported on the combination C/D vs. docetaxel
alone in a study of 250 men with metastatic AIPC and rising PSA levels
despite androgen suppression (testosterone levels < 50 ng/mL). The interim
analysis at 6 months - median F/U 9 months - favored C/D over D with a
> 50% decline in PSA in
58% vs. 49% of men, and an objective response in 28% vs. 20%,
respectively. Toxicity was less in the C/D arm. Neither difference was at
a level of significance. A later report of overall survival and PFS will
be forthcoming.
«
Back to Article List
|
